Advertisement

Table of Contents

December 06, 2018; 132 (23)

BLOOD COMMENTARIES

  • Natural, not immune; classical, not alternative
    Theodore E. Warkentin
  • DUO delivers for duvelisib
    Jennifer R. Brown
  • How deep is the myeloma iceberg?
    Jesús F. San-Miguel and Bruno Paiva
  • CiTE antibody for AML
    Michael P. Rettig and John F. DiPersio
  • TLT-1: please release me, let me go
    Yotis A. Senis
  • Stool can soften GVHD
    Mette D. Hazenberg

PLENARY PAPER

BLOOD SPOTLIGHT

CLINICAL TRIALS AND OBSERVATIONS

  • The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
    The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
    Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott Lunin, Francesco Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P. Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia M. Kelly, Barry Turnbull and Stephan Stilgenbauer

LYMPHOID NEOPLASIA

  • Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
    Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
    Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie-Lorraine Chretien, Thomas Dejoie, Sabrina Maheo, Anne-Marie Stoppa, Brigitte Pegourie, Lionel Karlin, Laurent Garderet, Bertrand Arnulf, Chantal Doyen, Nathalie Meuleman, Bruno Royer, Jean-Richard Eveillard, Lotfi Benboubker, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Brechignac, Brigitte Kolb, Cecile Fohrer, Mohamad Mohty, Margaret Macro, Paul G. Richardson, Victoria Carlton, Martin Moorhead, Tom Willis, Malek Faham, Kenneth C. Anderson, Jean-Luc Harousseau, Xavier Leleu, Thierry Facon, Philippe Moreau, Michel Attal, Hervé Avet-Loiseau and Nikhil Munshi
  • Subclonal <em>TP53</em> copy number is associated with prognosis in multiple myeloma
    Subclonal TP53 copy number is associated with prognosis in multiple myeloma
    Vallari Shah, David C. Johnson, Amy L. Sherborne, Sidra Ellis, Frances M. Aldridge, Julie Howard-Reeves, Farzana Begum, Amy Price, Jack Kendall, Laura Chiecchio, Suvi Savola, Matthew W. Jenner, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Gareth J. Morgan, Faith E. Davies, Richard S. Houlston, Gordon Cook, David A. Cairns, Graham Jackson and Martin F. Kaiser on behalf of the National Cancer Research Institute Haematology Clinical Studies Group

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

TRANSPLANTATION

LETTER TO BLOOD

BLOOD WORK